Xarelto “Complete Response” No Surprise, But Does FDA Want Data, A REMS Or Both?
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval could be pushed out to 2010 if the agency wants to review data from the ATLAS study, which completed too late to get into the NDA package.